Literature DB >> 2941260

Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.

D Galante, C Pennucci, S Esposito, D Barba.   

Abstract

A total of 375 Gram-negative bacterial strains were isolated from midstream urine specimens of the same number of patients affected by urinary tract infections. All bacteria were identified by standard bacteriological methods and their susceptibility to six quinoline derivatives (ciprofloxacin, cinoxacin, norfloxacin, oxolinic acid, pipemidic acid, nalidixic acid) was studied by determining the MICs and MBCs for each compound using a miniaturized dilution broth method in microtitre plates and twofold dilutions of each drug from 256 to 0.12 mcg/ml. Ciprofloxacin, a new quinoline carboxylic acid compound structurally related to nalidixic acid, showed a much higher antibacterial activity against all bacterial strains under examination, including Pseudomonas, than the other compounds, except for norfloxacin. The MIC90 and MBC90 of ciprofloxacin never exceeded 1 mcg/ml with any of the bacterial species; and MBC/MIC ratios were very low, which represents an important clinical advantage. Only norfloxacin showed comparable effectiveness. No bacterial strain showed resistance to the drug and the MIC90 and MBC90 never exceeded 8 mcg/ml.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2941260

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  3 in total

1.  Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.

Authors:  S Esposito; D Galante; D Barba; W Bianchi; R Gagliardi; R Giusti
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 2.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 3.  Quinolones: from antibiotics to autoinducers.

Authors:  Stephan Heeb; Matthew P Fletcher; Siri Ram Chhabra; Stephen P Diggle; Paul Williams; Miguel Cámara
Journal:  FEMS Microbiol Rev       Date:  2011-03       Impact factor: 16.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.